TITLE

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double- blind, placebo-controlled study

AUTHOR(S)
Kraus, M. A.; Schäfer, A.; Schöttker, K.; Keicher, C.; Weissbrich, B.; Hofbauer, I.; Scheurlen, M.
PUB. DATE
April 2008
SOURCE
Gut;Apr2008, Vol. 57 Issue 4, p531
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Interferon-induced depression represents a major complication in antiviral treatment of chronic hepatitis C virus (HCV) infection. Aim: To evaluate in a placebo-controlled study the efficacy of a selective serotonin reuptake inhibitor (SSRI) in HCV patients on antiviral therapy with interferon-associated depression. Methods: 100 HCV outpatients were included in a randomised, double-blind, placebo-controlled study. During interferon therapy (peginterferon alfa-2b plus ribavirin), depression was monitored using the Hospital Anxiety and Depression Scale (HADS). Patients with clinically relevant interferon-induced depression (HADS ⩾9) were randomly assigned to placebo or citalopram )SSRI, 20 mg/day). Results: In 28 patients (28%), HADS scores increased to >8 during interferon therapy. They were treated with placebo (n = 14) or SSRI (n = 14). HADS scores declined significantly in SSRI patients within four weeks of therapy (p<0.001) but not in placebo patients. This difference between subgroups was statistically significant (p = 0.032). Unblinding became necessary in five placebo patients as a result of intolerable depression. Rescue medication (20 mg citalopram) led to a significant decrease in HADS scores (p = 0.008). All citalopram patients were able to complete interferon therapy as planned. As an interim analysis showed a significant superiority of SSRI over placebo, the study was terminated prematurely. Three patients, who became depressed afterwards, were treated in an unblinded fashion with citalopram. Conclusions: The findings demonstrate clearly that citalopram treatment is highly effective in HCV patients on interferon therapy, when initiated after the onset of clinically relevant depressive symptoms. This suggests that a general SSRI prophylaxis is not necessary in these patients.
ACCESSION #
31654680

 

Related Articles

  • Practical Consequences of Hepatitis C Virus Quasispecies for Target-Specific Antivirals. Fanning, Liam J. // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p797 

    The author reflects on the consequences of Hepatitis C virus (HCV) quasispecies which provide an innate capacity to evade endogenous, as well as exogenous challenges. HCV inhibitor, according to the author, is a very important issue of resistant viruses. Furthermore, the quasispecies diversity...

  • Tumor Necrosis Factor-a Promoter Polymorphism at Position --308 Predicts Response to Combination Therapy in Hepatitis C Virus Infection. Chia-yen Dai; Wan-Long Chuang; Wen-Yu Chang; Shinn-cherng Chen; Li-Po Lee; Ming-Yen Hsieh; Nai-Jen Hou; Zu-Yau Lin; Jee-Fu Huang; Ming-Yuh Hsieh; Liang-Yen Wang; Ming-Lung Yu // Journal of Infectious Diseases;1/1/2006, Vol. 193 Issue 1, p98 

    The G→A transition in the tumor necrosis factor (TNF)- αa promoter region at position -308 (TNF3O8.2) and -238 (TNF238.2) were determined in 141 patients with chronic hepatitis C virus (HCV) infection. Patients received combination therapy with high-dose interferon (IFN)-α and...

  • Providing treatment for hepatitis C in an Australian district centre. Ewart A; Harrison L; Joyner B; Safe A // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p180 

    Hepatitis C virus (HCV) poses a major public health problem world wide. The introduction of combined therapy (interferon and ribavirin) and the recent development of pegylated interferon have offered the opportunity to alter the natural history of HCV, potentially reducing morbidity and...

  • Providing treatment for hepatitis C in an Australian district centre. Ewart A; Harrison L; Joyner B; Safe A // Postgraduate Medical Journal;Mar2004, Vol. 80 Issue 941, p180 

    Hepatitis C virus (HCV) poses a major public health problem world wide. The introduction of combined therapy (interferon and ribavirin) and the recent development of pegylated interferon have offered the opportunity to alter the natural history of HCV, potentially reducing morbidity and...

  • Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon. Hazari, Sidhartha; Taylor, Lizeth; Haque, Salima; Garry, Robert F.; Florman, Sander; Luftig, Ronald; Regenstein, Frederic; Dash, Srikanta // Virology Journal;2007, Vol. 4, p89 

    Background: Alpha interferon in combination with ribavirin is the standard therapy for hepatitis C virus infection. Unfortunately, a significant number of patients fail to eradicate their infection with this regimen. The mechanisms of IFN-resistance are unclear. The aim of this study was to...

  • siRNAs: Potential therapeutic agents against Hepatitis C Virus. Ashfaq, Usman A.; Yousaf, Muhammad Z.; Aslam, Maida; Ejaz, Rahat; Jahan, Shah; Ullah, Obaid // Virology Journal;2011, Vol. 8 Issue 1, p276 

    Hepatitis C virus is a major cause of chronic liver diseases which can lead to permanent liver damage, hepatocellular carcinoma and death. The presently available treatment with interferon plus ribavirin, has limited benefits due to adverse side effects such as anemia, depression and "flu-like"...

  • The function and evolution of the restriction factor viperin in primates was not driven by lentiviruses. Lim, Efrem S.; Wu, Lily I.; Malik, Harmit S.; Emerman, Michael // Retrovirology;2012, Vol. 9 Issue 1, p55 

    Background: Viperin, also known as RSAD2, is an interferon-inducible protein that potently restricts a broad range of different viruses such as influenza, hepatitis C virus, human cytomegalovirus and West Nile virus. Viperin is thought to affect virus budding by modification of the lipid...

  • Long term changes in liver histology following treatment of chronic hepatitis C virus. Shiffman, Mitchell L.; Sterling, Richard K.; Contos, Melissa; Hubbard, Sarah; Long, April; Luketic, Velimir A.; Stravitz, R. Todd; Fuchs, Michael; Sanyal, Arun J. // Annals of Hepatology: Official Journal of the Mexican Associatio;Jul/Aug2014, Vol. 13 Issue 4, p340 

    Background and aims. The histologic hallmarks of chronic HCV include inflammation and fibrosis. The impact of interferon therapy on liver histology was evaluated. Material and methods. The study population consisted of 348 patients with chronic HCV who underwent a baseline liver biopsy, received...

  • Serum Serotonin Levels are Associated with Antiviral Therapy Outcomes in Patients with Chronic Hepatitis C. Loftis, Jennifer M.; Morasco, Benjamin J.; Menasco, Daniel; Fuchs, Dietmar; Strater, Max; Hauser, Peter // Open Infectious Diseases Journal;2010, Vol. 4, p132 

    The role of serotonin in contributing to viral clearance has not been investigated in patients with chronic hepatitis C (HCV). In this prospective study we collected blood samples from 39 patients prior to and during antiviral therapy. Participants completed mood rating scales to monitor...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics